Therapeutics News and Research

RSS

Enhancing mRNA lifespan: A step forward in therapeutic development

mRNA-based therapeutics and vaccines are the new hope in the fight against incurable diseases. A commonly used strategy in the development of messenger RNA (mRNA) medicine is based on the destruction of disease-causing mRNA.

16 Oct 2024

Study provides detailed analysis of mRNA vaccine circulation and breakdown

A study led by researchers from RMIT University and the Doherty Institute has provided the first detailed analysis of how mRNA vaccines circulate and break down in the human bloodstream.

16 Oct 2024

Shift Bioscience raises $16 M to advance cell simulation AI platform

Shift Bioscience is a biotech company using generative AI models to understand how activation of different genes can reverse the aging process. This research is a fundamental step forward in designing more effective drugs to treat age-related diseases.

From Shift Bioscience 16 Oct 2024

Antibody engineering drives innovation in drug development

Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033).

16 Oct 2024

NYU Langone researchers address the challenges of heart failure in cancer patients

A new scientific statement issued today by the Heart Failure Society of America highlights a critical connection between heart failure (HF) and cancer, with shared mechanisms contributing to the incidence and progression of both diseases.

16 Oct 2024

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.

From Antiverse 16 Oct 2024

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

Ubiquigent Limited (“Ubiquigent”), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced a strategic partnership with Alleo Labs Corp. (“Alleo”), a pioneer in using artificial intelligence (AI) to develop new therapeutics for neurological diseases.

From Ubiquigent Limited 16 Oct 2024

Surface contamination, not air, poses nut allergy threat

There is no evidence for the commonly held belief that nut allergens can be spread through aircraft ventilation systems, say allergy and aviation medicine specialists in an evidence review published in the Archives of Disease in Childhood.

15 Oct 2024

Experimental drug RK-33 shows promise in treating breast cancer bone metastasis

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown to help treat other types of cancer and viral illnesses.

15 Oct 2024

Emory University researchers shift focus to neuroinflammation in Alzheimer's treatment

For decades, Alzheimer's research has focused on examining amyloid plaques in the brain and prescribing antibody therapeutics that remove the plaques to slow cognitive decline in patients.

15 Oct 2024

De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination

Rapid Novor has published a study that highlights the power of combining de novo antibody protein sequencing with conventional proteomics to uncover functional and neutralizing antibodies in human plasma following SARS-CoV-2 vaccination.

From Rapid Novor Inc 14 Oct 2024

Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the appointments of Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Chair of the Board.

From Calluna Pharma 14 Oct 2024

Exploring innovations in cardiovascular medicine at TCT MedTech Forum

As the pace of change accelerates in healthcare, the most pressing questions in cardiovascular medicine demand immediate answers.

12 Oct 2024

Innovative nanodiscs offer less invasive method for deep brain stimulation

Novel magnetic nanodiscs could provide a much less invasive way of stimulating parts of the brain, paving the way for stimulation therapies without implants or genetic modification, MIT researchers report.

12 Oct 2024

MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024.

From MaxCyte, Inc. 11 Oct 2024

New research explores hydrogen sulfide as treatment for obesity

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related diseases, new research has concluded.

10 Oct 2024

The role of geroscience in understanding Alzheimer’s Disease

For more than 30 years, researchers have identified and quantified genetic and lifestyle factors for Alzheimer's Disease (AD) and other dementias. Despite extensive research, the fundamental mechanisms behind these neurodegenerative diseases are still not fully understood, and effective management of AD is taking longer than expected.

10 Oct 2024

Baylor scientist earns NIH grant for personalized microbiome treatments

Baylor University researcher Aaron Wright, Ph.D., has earned a $5.6 million National Institutes of Health (NIH) Director's Transformative Research Award for a project that he and collaborators hope could lead to personalized – and revolutionary – treatments for gut microbiome diseases like Irritable Bowel Syndrome (IBS), Crohn's, Ulcerative Colitis and more.

9 Oct 2024

Researchers uncover key bacteria driving success of fecal microbiota transplants

Fecal microbiota transplants, or FMTs, are a magic bullet for patients with recurring infections from Clostridioides difficile (C. diff), but researchers are only beginning to understand why.

9 Oct 2024

Researchers discover potential therapeutic approach for triple negative breast cancer

Triple negative breast cancer (TNBC) remains the most aggressive and deadly type of breast cancer, but new findings from cancer researchers at Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, are pointing the way toward therapeutic strategies that could be tested in clinical trials in the future.

9 Oct 2024

Therapeutics News and Research

Enhancing mRNA lifespan: A step forward in therapeutic development

Study provides detailed analysis of mRNA vaccine circulation and breakdown

Shift Bioscience raises $16 M to advance cell simulation AI platform

Antibody engineering drives innovation in drug development

NYU Langone researchers address the challenges of heart failure in cancer patients

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery

Surface contamination, not air, poses nut allergy threat

Experimental drug RK-33 shows promise in treating breast cancer bone metastasis

Emory University researchers shift focus to neuroinflammation in Alzheimer's treatment

De novo antibody protein sequencing reveals novel functional and neutralizing antibodies post-SARS-CoV-2 vaccination

Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board

Exploring innovations in cardiovascular medicine at TCT MedTech Forum

Innovative nanodiscs offer less invasive method for deep brain stimulation

MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer

New research explores hydrogen sulfide as treatment for obesity

The role of geroscience in understanding Alzheimer’s Disease

Baylor scientist earns NIH grant for personalized microbiome treatments

Researchers uncover key bacteria driving success of fecal microbiota transplants

Researchers discover potential therapeutic approach for triple negative breast cancer

Next-generation therapeutics eBook eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News